Bihua Chen's Form 4 Filing for BridgeBio Oncology Therapeutics - Pro Rata Distribution of Shares

This Form 4 filing reports changes in beneficial ownership of BridgeBio Oncology Therapeutics, Inc. (BBOT) by Bihua Chen, who serves as both a director and 10% owner. The filing details a complex pro rata distribution transaction on July 1, 2026, involving multiple investment vehicles. Chen disposed of 4,528,186 shares from Helix Holdings II LLC (the Sponsor) and acquired shares through various Cormorant Funds: 2,692,459 shares via Fund III, 1,704,862 shares via Fund V, and 130,865 shares via the Master Fund. All transactions were coded as "J" (other acquisition/disposition) with $0.00 price per share, indicating a non-cash distribution. Chen maintains indirect ownership of 1,905,046 shares through Fund IV. The filing includes extensive footnotes explaining the relationships between Chen, the Sponsor, and the Cormorant Funds, with Chen serving as managing member of the general partners and having voting and investment discretion over the shares held by these entities.